SavedAdd your journal

Journals / art / 2020 / Cilt: 35 - Sayı: 3

Decreased Bilirubin is Associated With Disease Activity of Primary Sjögren's Syndrome

Jing XIE
Zhencheng ZHANG
Yan LIANG
Zaixing YANG
Journal
art
Pages
351–356
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Serum bilirubin is decreased in pSS patients and may be a useful biomarker for reflecting pSS disease activity.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: This study aims to determine the serum bilirubin levels in primary Sjögren's syndrome (pSS) patients and to explore clinical significance of bilirubin in pSS.
📊
Key Findings & Data:Patients and methods: Retrospective analysis of electronic medical records was performed in 97 pSS patients (12 males, 85 females; mean age 54±15 years; range, 15 to 91 years) and 100 healthy controls (17 males, 83 females; mean age 51±14 years; range, 25 to 75 years).
💡
Conclusion & Impact:Conclusion: Serum bilirubin is decreased in pSS patients and may be a useful biomarker for reflecting pSS disease activity.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Objectives: This study aims to determine the serum bilirubin levels in primary Sjögren's syndrome (pSS) patients and to explore clinical significance of bilirubin in pSS. Patients and methods: Retrospective analysis of electronic medical records was performed in 97 pSS patients (12 males, 85 females; mean age 54±15 years; range, 15 to 91 years) and 100 healthy controls (17 males, 83 females; mean age 51±14 years; range, 25 to 75 years). Serum bilirubin and other variables were compared between pSS patients and healthy controls. The European League Against Rheumatism Sjögren's syndrome disease activity index (ESSDAI) was used to assess the disease activity of pSS, and ESSDAI ≥5 was defined as moderate to high activity. The relationship between bilirubin and ESSDAI was analyzed by Spearman's correlation analysis and multivariable logistic regression. Results: The median level of serum bilirubin was 9 μmol/L (interquartile range (IQR), 7-13 μmol/L) in pSS patients, much lower than healthy controls (median, IQR, 13, 10-18 μmol/L) (p<0.001). It was positively correlated with age (r=0.255, p=0.012), but negatively with immunoglobulin (Ig) A (r=-0.314, p=0.003), IgG (r=-0.265, p=0.015), erythrocyte sedimentation rate (r=-0.309, p=0.002) and ESSDAI (r=-0.342, p=0.001). Multivariate analysis revealed that increased bilirubin was independently associated with decreased risk of moderate to high disease activity (odds ratio, 95% confidence interval: 0.852, 0.730-0.955). Conclusion: Serum bilirubin is decreased in pSS patients and may be a useful biomarker for reflecting pSS disease activity.

🔖

Cite This Article

XIE, J., ZHANG, Z., LIANG, Y., YANG, Z. (2020). Decreased Bilirubin is Associated With Disease Activity of Primary Sjögren's Syndrome. art, Cilt: 35 - Sayı: 3, 351–356. https://ajindex.com/articles/142227

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Mariette X, Criswell LA. Primary Sjögren's Syndrome. N Engl J Med 2018;378:931-9.
  2. Seror R, Ravaud P, Bowman SJ, Baron G, Tzioufas A, Theander E, et al. EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome. Ann Rheum Dis 2010;69:1103-9.
  3. Seror R, Ravaud P, Mariette X, Bootsma H, Theander E, Hansen A, et al. EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome. Ann Rheum Dis 2011;70:968-72.
  4. Seror R, Theander E, Brun JG, Ramos-Casals M, Valim V, Dörner T, et al. Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). Ann Rheum Dis 2015;74:859-66.
  5. Seror R, Mariette X, Bowman S, Baron G, Gottenberg JE, Bootsma H, et al. Accurate detection of changes in disease activity in primary Sjögren's syndrome by the European League Against Rheumatism Sjögren's Syndrome Disease Activity Index. Arthritis Care Res (Hoboken) 2010;62:551-8.
  6. Kurimoto C, Kawano S, Tsuji G, Hatachi S, Jikimoto T, Sugiyama D, et al. Thioredoxin may exert a protective effect against tissue damage caused by oxidative stress in salivary glands of patients with Sjögren's syndrome. J Rheumatol 2007;34:2035-43.
  7. Norheim KB, Jonsson G, Harboe E, Hanasand M, Gøransson L, Omdal R. Oxidative stress, as measured by protein oxidation, is increased in primary Sjøgren's syndrome. Free Radic Res 2012;46:141-6.
  8. Pagano G, Castello G, Pallardó FV. Sjøgren's syndrome-associated oxidative stress and mitochondrial dysfunction: prospects for chemoprevention trials. Free Radic Res 2013;47:71-3.
  9. Wakamatsu TH, Dogru M, Matsumoto Y, Kojima T, Kaido M, Ibrahim OM, et al. Evaluation of lipid oxidative stress status in Sjögren syndrome patients. Invest Ophthalmol Vis Sci 2013;54:201-10.
  10. Boon AC, Hawkins CL, Coombes JS, Wagner KH, Bulmer AC. Bilirubin scavenges chloramines and inhibits myeloperoxidase-induced protein/lipid oxidation in physiologically relevant hyperbilirubinemic serum. Free Radic Biol Med 2015;86:259-68.
  11. Basiglio CL, Toledo FD, Boaglio AC, Arriaga SM, Ochoa JE, Sánchez Pozzi EJ, et al. Physiological concentrations of unconjugated bilirubin prevent oxidative stress-induced hepatocanalicular dysfunction and cholestasis. Arch Toxicol 2014;88:501-14.
  12. Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN. Bilirubin is an antioxidant of possible physiological importance. Science 1987;235:1043-6.
  13. Wu TW, Carey D,